This company has been acquired
Jounce Therapeutics Past Earnings Performance
Past criteria checks 0/6
Jounce Therapeutics's earnings have been declining at an average annual rate of -34.3%, while the Biotechs industry saw earnings growing at 30.5% annually. Revenues have been declining at an average rate of 13.5% per year.
Key information
-34.3%
Earnings growth rate
-23.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -13.5% |
Return on equity | -27.8% |
Net Margin | -62.1% |
Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
We're A Little Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Rate
Jan 04Here's Why We're Watching Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Sep 20Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Jun 16We Think Jounce Therapeutics (NASDAQ:JNCE) Can Easily Afford To Drive Business Growth
Feb 23Jounce Therapeutics: A Favorable Risk-Reward Ahead Of Critical 2022 Catalysts
Dec 16News Flash: Analysts Just Made A Dazzling Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Aug 07Jounce Therapeutics: An Under The Radar And Undervalued Biotech
Jul 13Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE) Revenues
Jun 16Shareholders May Not Be So Generous With Jounce Therapeutics, Inc.'s (NASDAQ:JNCE) CEO Compensation And Here's Why
Jun 12Jounce Therapeutics EPS beats by $0.01, misses on revenue
May 04We're Hopeful That Jounce Therapeutics (NASDAQ:JNCE) Will Use Its Cash Wisely
May 03Jounce Therapeutics (NASDAQ:JNCE) Shareholders Have Enjoyed An Impressive 163% Share Price Gain
Mar 02News Flash: Analysts Just Made A Sizeable Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Mar 02Enrollment underway in Jounce Therapeutics' early-stage JTX-8064 study in solid tumors
Jan 13Have Insiders Sold Jounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Recently?
Jan 13Jounce Therapeutics: A Potential Roller Coaster
Dec 31A Look At Jounce Therapeutics' (NASDAQ:JNCE) CEO Remuneration
Dec 15Revenue & Expenses BreakdownBeta
How Jounce Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 22 | 82 | -51 | 36 | 44 |
30 Sep 22 | 0 | -132 | 35 | 44 |
30 Jun 22 | 0 | -131 | 34 | 43 |
31 Mar 22 | 25 | -102 | 34 | 47 |
31 Dec 21 | 27 | -91 | 34 | 39 |
30 Sep 21 | 89 | -25 | 34 | 38 |
30 Jun 21 | 89 | -20 | 34 | 36 |
31 Mar 21 | 64 | -44 | 34 | 30 |
31 Dec 20 | 62 | -44 | 34 | 36 |
30 Sep 20 | 0 | -102 | 34 | 40 |
30 Jun 20 | 119 | 22 | 37 | 54 |
31 Mar 20 | 137 | 43 | 34 | 36 |
31 Dec 19 | 148 | 57 | 34 | 35 |
30 Sep 19 | 168 | 77 | 33 | 57 |
30 Jun 19 | 63 | -29 | 31 | 16 |
31 Mar 19 | 65 | -27 | 33 | 33 |
31 Dec 18 | 65 | -27 | 32 | 33 |
30 Sep 18 | 58 | -35 | 31 | 9 |
30 Jun 18 | 62 | -31 | 30 | 35 |
31 Mar 18 | 63 | -30 | 30 | 34 |
31 Dec 17 | 72 | -17 | 29 | 32 |
30 Sep 17 | 79 | -5 | 26 | 29 |
30 Jun 17 | 78 | -1 | 23 | 25 |
31 Mar 17 | 57 | -11 | 21 | 25 |
31 Dec 16 | 37 | -23 | 17 | 19 |
30 Sep 16 | 17 | -38 | 15 | 29 |
Quality Earnings: JNCE is currently unprofitable.
Growing Profit Margin: JNCE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JNCE is unprofitable, and losses have increased over the past 5 years at a rate of 34.3% per year.
Accelerating Growth: Unable to compare JNCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JNCE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.7%).
Return on Equity
High ROE: JNCE has a negative Return on Equity (-27.81%), as it is currently unprofitable.